Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus
Shots:
- The first patient has been dosed in the P-III (VANIR) trial to evaluate MVA-BN RSV vaccine vs PBO in 20,000 adults aged ≥60yrs. with RSV at ~115 sites across the US & Germany. The results are expected in mid-2023, if the pre-defined no. of lower-respiratory tract disease events has occurred
- The primary objective of the study is to evaluate the efficacy of vaccine candidates against lower-respiratory tract disease caused by RSV
- In the P-II study, the vaccine showed a reduction in viral load in patients vaccinated with MVA-BN RSV, clinical symptoms were reduced & demonstrated efficacy of ~79% in preventing symptomatic RSV inf. The therapy was well-tolerated, induced broad and durable Ab & T-cell responses
Ref: Globe Newswire | Image: Bavarian Nordic
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
